Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-706 in advanced NSCLC
NCT07171606Phase 2Recruiting
- Sponsor
- 3SBio
- Start
- Oct 2025
- Primary completion
- Aug 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SSGJ-706 in non-small cell lung cancer (NSCLC), sponsored by 3SBio. Started Oct 2025; status: recruiting.
02
Drugs
SSGJ-706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07171606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07171606.